Benzinga.com10h
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...
Boston Scientific’s Watchman could be new option for patients post ablation: study
The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...
GlobalData on MSN13h
Boston Scientific reports outcomes from trial of LAAC device
The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
TCTMD22h
OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain
LAAO—performed with the Watchman FLX device (Boston Scientific) at the same time as ablation or in a sequential manner—lowered the risk of bleeding while providing noninferior efficacy in terms of ...
BSX : WATCHMAN FLX Device Reduces Bleeding Risk, Matches Stroke Prevention After Cardiac Ablation
Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...
MedPage Today on MSN6h
Left Atrial Appendage Closure Reduced Bleeding After Afib Ablation
Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...
Seeking Alpha25d
Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Regulatory approvals and trials, particularly for WATCHMAN FLX Pro and FARAPULSE, are crucial for future performance and could introduce short-term volatility. Given the rich valuation and ...